5 Apr 2018
Dr Miroslav Reljanović

Dr. Miroslav Reljanović is a medical doctor and a board-certified neurologist. Whilst practicing as a physician in a large WHO Collaborating Centre in Zagreb, he was the clinical investigator in numerous Phase II and III studies in the field of neurology and a consultant to various pharmaceutical companies. Miro founded Ergomed in 1997 and he introduced the novel Study Site Coordination model as an intrinsic part of the conduct of clinical studies.

Miro successfully introduced the first European co-development business model and he has completed several partnerships with European and North American listed biopharmaceutical companies. Miro co-founded PrimeVigilance in 2008 and it soon became a leading specialist vendor of contracted pharmacovigilance services to the pharmaceutical industry.

Miro led Ergomed through a successful IPO on the AIM market of the London Stock Exchange in July 2014 and the subsequent completion of five acquisitions and a secondary offering.

Miro is a director of Asarina Pharma AB (listed on the Nasdaq First North exchange), and Modus Therapeutics Holding AB, both Swedish-incorporated companies in which Ergomed plc has an equity stake through co-development arrangements.

Miro brings to the Board his in-depth experience in clinical development and the operational execution of drug development, as well as a detailed knowledge of the Group and its
operations.

Miro is Chair of Ergomed’s Nomination Committee.